X

Drug Profile

AM 3301

Alternative Names: AM3301; ME 3301

Latest Information Update: 31 Jul 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Meiji Seika Kaisha
Developer Amalyte Pharmaceuticals
Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
Mechanism of Action Cytokine inhibitors; Inflammation mediator inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Allergic rhinitis; Hypersensitivity; Ulcerative colitis

Most Recent Events

01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma
25 Feb 2011 Phase-II development is ongoing
11 Jun 2009 AM 3301 licensed to Amalyte Pharmaceuticals worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com